Nuveen Asset Management, LLC Selecta Biosciences Inc Transaction History

Nuveen Asset Management, LLC

  • $329 Billion
  • Q1 2024

A detailed history of Nuveen Asset Management, LLC transactions in Selecta Biosciences Inc stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 490,320 shares of SELB stock, worth $411,868. This represents 0.0% of its overall portfolio holdings.

Number of Shares
490,320
Previous 490,320 -0.0%
Holding current value
$411,868
Previous $338,000 21.6%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
SELL
$1.02 - $1.23 $186,068 - $224,376
-182,420 Reduced 27.12%
490,320 $519,000
Q2 2023

Aug 14, 2023
BUY
$1.04 - $1.4 $699,649 - $941,835
672,740 New
672,740 $753,000
Q2 2022

Aug 15, 2022
SELL
$0.67 - $1.4 $1.39 Million - $2.9 Million
-2,070,638 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$1.23 - $3.31 $42,382 - $114,052
-34,457 Reduced 1.64%
2,070,638 $3.02 Million
Q4 2021

Feb 14, 2022
SELL
$2.89 - $4.43 $215,073 - $329,680
-74,420 Reduced 3.41%
2,105,095 $6.36 Million
Q3 2021

Nov 12, 2021
BUY
$3.36 - $4.62 $102,275 - $140,628
30,439 Added 1.42%
2,179,515 $9.7 Million
Q2 2021

Aug 16, 2021
BUY
$2.82 - $5.01 $829,706 - $1.47 Million
294,222 Added 15.86%
2,149,076 $8.98 Million
Q1 2021

May 17, 2021
BUY
$2.92 - $5.07 $4.24 Million - $7.37 Million
1,452,681 Added 361.21%
1,854,854 $8.39 Million
Q4 2020

Feb 16, 2021
BUY
$1.64 - $3.42 $211,947 - $441,987
129,236 Added 47.35%
402,173 $1.22 Million
Q3 2020

Nov 16, 2020
BUY
$2.18 - $2.84 $3,224 - $4,200
1,479 Added 0.54%
272,937 $677,000
Q2 2020

Aug 14, 2020
BUY
$1.83 - $4.06 $496,768 - $1.1 Million
271,458 New
271,458 $771,000

Others Institutions Holding SELB

# of Institutions
68
Shares Held
41.4M
Call Options Held
16.8K
Put Options Held
0
View Full List

About SELECTA BIOSCIENCES INC

SELB Quotes by TradingView
  • Ticker SELB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 152,712,992
  • Market Cap $128M
  • Description
  • Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...
More about SELB
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email